Pirenoxine acts to prevent and inhibit the denaturation of lens proteins, a process that leads to lens opacity and the development of cataracts.
By blocking the binding of quinone compounds to lens proteins, pirenoxine helps slow down the progression of early-stage senile (age-related) cataracts, maintaining lens transparency and visual clarity.
Most reactions are mild and transient:
Rarely:
If symptoms persist or worsen, discontinue use and consult an ophthalmologist.


